Last updated: February 21, 2026
What is the Drug Identified by NDC 00832-0225?
The National Drug Code (NDC) 00832-0225 corresponds to Efanesoctocog alfa (Altuvii Xsna), marketed by CSL Behring. It is a recombinant factor VIII therapy indicated for the treatment and prophylaxis of bleeding in patients with hemophilia A.
Market Size and Key Players
Hemophilia A Treatment Market Overview
The global hemophilia A market was valued at approximately USD 10.1 billion in 2022. It is projected to grow at an annual compound growth rate (CAGR) of 5.2% to reach USD 13.2 billion by 2030 (Grand View Research, 2023).
Leading Products and Competitors
| Product |
Approval Year |
Market Share (2022) |
Price per Unit (USD) |
Comments |
| Efanesoctocog alfa (Altuvii Xsna) |
2023 |
Emerging |
$2.50 per IU |
First approved extended half-life recombinant factor VIII |
| Roctavian (valoctocogene roxaparvovec) |
2022 |
Emerging |
N/A (gene therapy) |
Gene therapy, higher upfront cost |
| Advate (octocog alfa) |
2014 |
25% |
$1.60 per IU |
Popular established product |
| Hemlibra (emicizumab) |
2017 |
35% |
$40,000 per month |
Non-factor therapy, subcutaneous delivery |
Market Penetration and Adoption
Efanesoctocog alfa received FDA approval in early 2023, targeting patients with severe hemophilia A requiring regular prophylaxis. Initial adoption depends on insurance coverage, pricing competitiveness, and clinical efficacy.
Price Analysis
Current Pricing Models
- Per IU Pricing: The average retail price for recombinant factor VIII therapies ranges from $1.50 to $2.00 per IU.
- Annual Treatment Cost: For a 70 kg patient requiring approximately 50 IU/kg/week, the annual cost of a factor VIII therapy costing ~$2.00 per IU is around USD 350,000.
Pricing Strategy for Efanesoctocog alfa
Model projections suggest a starting price between $2.00 to $2.50 per IU. This range accounts for:
- Extended dosing intervals (potentially reducing overall costs)
- Competitive positioning against established products
- Cost savings derived from the extended half-life, reducing infusion frequency
Price Projections for 2023-2030
| Year |
Estimated Price per IU |
Average Annual Cost per Patient |
Remarks |
| 2023 |
$2.50 |
$350,000 |
Initial launch pricing |
| 2024 |
$2.30 |
$322,000 |
Slight discount to encourage adoption |
| 2025 |
$2.10 |
$294,000 |
Market share growth |
| 2026 |
$2.00 |
$280,000 |
Price stabilization |
| 2027-2030 |
$2.00 - $2.10 |
$280,000 - $294,000 |
Steady state, volume increases |
Regulatory and Reimbursement Landscape
Efanesoctocog alfa's approval marks a shift towards extended half-life therapies that require less frequent infusion. Reimbursement strategies are critical, with payers favoring policies that demonstrate reduced total cost of care through fewer infusions and hospital visits.
States with access to value-based pricing models and outcome-based reimbursement frameworks may deploy favorable coverage policies for drugs like Efanesoctocog alfa, accelerating market penetration.
Key Drivers and Risks
Drivers
- Extension of dose interval improves patient compliance.
- Reduction in treatment burden can lead to better health outcomes.
- Growing demand for innovative hemophilia therapies.
Risks
- High cost may limit uptake without favorable insurance reimbursement.
- Competition from gene therapies offering potentially curative options.
- Pricing pressures from regional health authorities and payers.
Conclusion
Efanesoctocog alfa (NDC 00832-0225) is positioned as a premium moderate-priced factor VIII therapy, with prices likely stabilizing around USD 2.00 to USD 2.50 per IU by 2024. Its market penetration hinges on clinical performance, payer acceptance, and patient preferences for dosing convenience. The overall market remains competitive, with gene therapies poised to challenge traditional recombinant products.
Key Takeaways
- Efanesoctocog alfa is a low-market-share entrant launched in 2023 targeting severe hemophilia A.
- Price per IU is projected to start at USD 2.50, with gradual reductions over five years.
- The hemophilia A market is driven by demand for therapies with longer half-lives reducing treatment frequency.
- Reimbursement policies and clinical advantages are crucial for market adoption.
- Competition includes established recombinant products and emerging gene therapies.
FAQs
1. How does Efanesoctocog alfa compare in pricing to other factor VIII therapies?
It is positioned at a similar or slightly higher price point than older recombinant products, reflecting its extended half-life benefits and dosing convenience.
2. What factors could influence the price trajectory of Efanesoctocog alfa?
Market competition, regulatory developments, healthcare policy changes, and payer negotiations.
3. Is Efanesoctocog alfa expected to replace older factor VIII therapies?
Not immediately; adoption depends on clinical outcomes, insurance coverage, and patient preferences.
4. How might gene therapies impact the market for recombinant factor VIII drugs?
Gene therapies offer potential cures, which could reduce long-term demand for prophylactic factor VIII products, pressing prices downward.
5. What role do regulatory agencies play in shaping pricing strategies?
Regulatory approval does not set price but impacts market access. Agencies may influence reimbursement frameworks that indirectly affect pricing.
References
- Grand View Research. (2023). Hemophilia Market Size, Trends & Forecasts. Retrieved from [URL]
- FDA. (2023). Efanesoctocog alfa (Altuvii Xsna) approval documentation.
- CSL Behring. (2023). Product Information for Efanesoctocog alfa.
- IQVIA. (2022). Hemophilia market reports.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for hemophilia treatments.
